Supernus Pharmaceuticals Current Ratio 2011-2020 | SUPN

Supernus Pharmaceuticals current ratio from 2011 to 2020. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Supernus Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2020-03-31 $0.56B $0.17B 3.31
2019-12-31 $0.47B $0.16B 2.94
2019-09-30 $0.43B $0.15B 2.85
2019-06-30 $0.39B $0.14B 2.72
2019-03-31 $0.42B $0.15B 2.77
2018-12-31 $0.49B $0.16B 3.06
2018-09-30 $0.39B $0.14B 2.82
2018-06-30 $0.29B $0.10B 2.74
2018-03-31 $0.58B $0.12B 4.90
2017-12-31 $0.23B $0.12B 1.86
2017-09-30 $0.19B $0.11B 1.82
2017-06-30 $0.17B $0.09B 1.94
2017-03-31 $0.15B $0.08B 1.83
2016-12-31 $0.15B $0.08B 1.88
2016-09-30 $0.14B $0.07B 1.93
2016-06-30 $0.11B $0.07B 1.69
2016-03-31 $0.09B $0.06B 1.69
2015-12-31 $0.11B $0.06B 1.86
2015-09-30 $0.10B $0.04B 2.35
2015-06-30 $0.11B $0.04B 2.89
2015-03-31 $0.10B $0.03B 3.69
2014-12-31 $0.11B $0.03B 3.87
2014-09-30 $0.10B $0.02B 4.65
2014-06-30 $0.07B $0.02B 3.75
2014-03-31 $0.08B $0.03B 2.95
2013-12-31 $0.10B $0.03B 3.68
2013-09-30 $0.10B $0.03B 4.10
2013-06-30 $0.11B $0.02B 6.90
2013-03-31 $0.08B $0.03B 2.83
2012-12-31 $0.09B $0.02B 3.98
2012-09-30 $0.06B $0.03B 2.56
2012-06-30 $0.08B $0.02B 3.56
2012-03-31 $0.04B $0.02B 1.93
2011-12-31 $0.05B $0.02B 2.63
2011-09-30 $0.00B 0.00
2011-06-30 $0.00B 0.00
2011-03-31 $0.00B 0.00
2010-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.240B $0.393B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $12.396B 4.60
Dr Reddy's Laboratories (RDY) India $8.763B 20.98
Mylan (MYL) United States $8.235B 3.54
Bausch Health Cos (BHC) Canada $6.508B 4.31
ASPEN PHARMACR (APNHY) South Africa $3.852B 0.00
BridgeBio Pharma (BBIO) United States $3.612B 0.00
Amphastar Pharmaceuticals (AMPH) United States $1.013B 52.19
Assembly Biosciences (ASMB) United States $0.759B 0.00
Homology Medicines (FIXX) United States $0.694B 0.00
Voyager Therapeutics (VYGR) United States $0.480B 0.00
Personalis (PSNL) United States $0.451B 0.00
CymaBay Therapeutics (CBAY) United States $0.241B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.205B 0.28
Sol-Gel Technologies (SLGL) Israel $0.177B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.087B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.072B 0.00
Akorn (AKRXQ) United States $0.052B 2.79
Teligent (TLGT) United States $0.014B 0.00